## DAVID PLATT, Ph.D.

david@pharmalectin.com

(617)-510-2539





This report contains forward-looking statements concerning, among other things, possible applications for marketing approval and other regulatory matters, clinical trials, plans for the development of Pharmalectin products, and business development strategies. These forward-looking statements employ terms such as ‘intends, expects, plans, estimates, anticipates, should, can, and believes’. These forward-looking statements involve risks and uncertainties. Actual results may differ materially from those predicted by the forward-looking statements because of various factors and possible events. Company risks include lack of FDA or any other regulatory approval for our human products, difficulty and uncertainty in obtaining regulatory approval, uncertainty about future physician and market acceptance of our product, limited manufacturing capabilities, limited capital resources, and lack of commercial pharmaceutical experience. In addition, we are subject to industry risks including the fact that our industry is highly regulated, keenly competitive, and subject to pricing uncertainty because of third-party reimbursement issues and controls on health care spending.

# The *BIG* Problem




## Worldwide Pandemic

- Human Toll *(at 09/20/20)*:
  **>30,000,000 Infected**
  **~1,000,000 Fatal**
- Economic Cost -32.9% US GDP in Q2 2020
  and deep global recession.
- No Vaccine.
- No Approved Treatment.

BioXyTran Inc.

Fully reporting
97M shares
1,350 shareholders
85% insider owned
Assets
BXT-25Rx (platform)
BXT-10Rx (platform)
MDX Viewer (platform)

*Fully owned subsidiary*

PHARMALECTIN INC

Fully reporting (consolidated)
15M shares
1 shareholder
Assets
ProLectin-Rx (COVID-19 indications)
Security
BXT-101 Cancer Metastasis indication

PHARMALECTIN INC

Based on an exclusive agreement and subject to funding, Pharmalectin is a 50%-50% Joint Venture between Bioxytran, Inc. and **Pharmalectin Partners LLC**, a Special Purpose Vehicle managed by ***Black Diamond Financial Group LLC***.

# Life Cycle of a Virus



https://www.youtube.com/watch?v=oXzwtGFyBik

# The Problems with COVID-19

- ✓ Currently No Vaccine.
- ✓ Future Vaccines Targeting 50% Effectiveness.
- ✓ Death Rate Unacceptably High.
- ✓ Permanent Fibrotic Damage to Lungs and Organs.
- ✓ No Clear Effective Treatment (early to late stage).



# Therapeutic Approaches for COVID-19

**6,015 Clinical Ongoing Trials** *(at 9/16/2020)*



# Immune System Tags Virus for Destruction




https://medicalxpress.com/news/2020-05-dont-antibodies-immunity.html

# Galectin Inhibitor Tags Virus for Elimination



# Research & Development

PHARMALECTIN is an emerging biotech company repurposing an FDA approved technology and clinical trials as the base for a Platform Technology, allowing to leapfrog into Phase III clinical trials.

| Description | Designation | Patients | Asset Type |
|---|---|---|---|
| Galectin Inhibitor | CLL (blood cancer) | 140 | Phase III |

## Current Status

- Predicted highly effective.
- Unique technology and IP, based on extensive know-how.
- Limited IRB clinical trial – *in progress*.
- Manufacturing – *formulation readiness*.
- FDA Fast Track Approval – *in process (IND phase III)*.

# Recent Publications


Original Article

The role of galectins ir
systemic literature rev


RSC Advances

PAPER

Understa
potential
*in silico*

1. Introduction


Immunopathology of gale
target in COVID-19 [versior
review]


A potential role for Galectin-3 inhibitors in the treatment of COVID-19

ABSTRACT

INTRODUCTION


Can We trust Big Pharma to Find a Cure for COVID-19?

US government's Covid-19 funding

The US Government has spent over $10 billion through Operation Warp Speed (OWS)

- Focused on ensuring the manufacturing supply of promising vaccines.
- Entirely directed to big pharma.

## 2020 Peer Reviewed Articles Galectin and COVID-19

- The role of galectins in virus infection - A systematic literature review.
- Immunopathology of galectin-3 an increasingly promising target in COVID-19.
- Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein.
- A potential role for Galectin-3 inhibitors in the treatment of COVID-19.

# End-to-End Solution

| PHARMALECTIN INC *Treatment* | ProLectin-M *Oral* | ProLectin-I *Intravenous* | ProLectin-A *Intravenous** | ProLectin-F *Intravenous* |
|---|---|---|---|---|
| **Combination* | | | MDX-Viewer | |



# Clinical Trials

- Admittance completed on 9/19/20.
- Early Stage COVID-19 Patients.
- Reduction of Viral Load.
- Time to Full Recovery.



U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies | About Studies | Submit Studies | Resources | About Site | PRS Login

Home > Search Results > Study Record Detail

Save this study

**Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)**

ClinicalTrials.gov Identifier: NCT04512027

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Recruitment Status : Not yet recruiting
First Posted : August 13, 2020
Last Update Posted : August 27, 2020

See Contacts and Locations

**Sponsor:**
Composite Interceptive Med Science

**Collaborator:**
Pharmalectin Inc, a subsidiary of Bioxytran Inc

**Information provided by (Responsible Party):**
Composite Interceptive Med Science

Study Details | Tabular View | No Results Posted | Disclaimer | How to Read a Study Record

**Study Description**

Go to

Brief Summary:
A randomised controlled trial of open label Prolectin-M; a (1-6)-alpha-D-Mannopyranose among patients with RT PCR positive COVID-19 patients.

| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| COVID-19 | Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class<br>Other: Standard of Care | Not Applicable |

Detailed Description:

SarsCoV2 has infected over 20 million people worldwide. The virus has a unique protein structure enabling it to rapidly infect and spread among the population. COVID19 is a global health emergency and has affected lives of all people irrespective of being infected. There are no proven therapies and a vaccine is yet to be approved for wide public usage.

Our study aims to test a hypothesis of physically blocking the spike protein from infecting the human cells, thus promoting its rapid excretion from the infected person.

We will randomise 10 subjects in this proof of concept trial and test the hypothesis by measuring the effect of Prolectin-M; a (1-6)-alpha-D-Mannopyranose in reducing the viral copy numbers over 5 days of

https://www.clinicaltrials.gov/ct2/show/NCT04512027

**CEO David Platt PhD:** carbohydrate chemistry expert, founded four publicly traded companies, raised $150m in public markets, created $1B in shareholder value, and led development of two drug candidates from concept through to Phase II clinical trials.

**CFO Ola Soderquist CPA, MSA, MBA:** >30 years multi-industry financial experience.

**EVP BD Mike Sheikh:** >10 years of business development in life sciences. Broker and Research Analyst.

**PM Dir Veronika Tyukova MBA:** >15 years of PM in Hi-Tech, Manufacturing and Commercialization.

**Director Anders Utter MBA:** Audit Committee Chair, >25 years of managerial finance and accounting in medical devices and manufacturing.

**Director Alan Hoberman PhD:** Executive Director of Site Operations and Toxicology at Charles River Laboratories.

**Director Henry Esber PhD:** >35 years experience in oncology, tumor immunology, immunotherapy, toxicology and regulatory affairs.

**Director Dale Conaway DVM:** Veterinary Medical Officer, Federal Research.

**Medical Advisor Avraham Mayevsky PhD:** worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology; and professor at the Faculty of Life Sciences, Bar-Ilan University, Israel.

**Medical Advisor Juan Carlos Lopez-Talavera PhD:** >20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases.

**Medical Advisor Hana Chen-Walden MD:** >30 years experience in pharmaceutical regulatory affairs in US and Europe.

# Time-line and Budget

| Product | Month 2 | Month 4 | Month 6 |
|---|---|---|---|
| ProLectin-M | CMC TOX IND | Phase II/III | Licensing |
| ProLectin-I | CMC TOX IND | | |
| ProLectin-F | CMC | TOX Pre-IND | |
| ProLectin-A | | GLP | |

| in million USD | ProLectin-Rx |
|---|---|
| CMC/Manufacturing | $ 1.1 |
| Toxicity screening | $ 0.6 |
| IND submission | $ 0.2 |
| Clinical trials | $ 2.1 |
| Licensing | --- |
| Overhead (25%) | $ 1.0 |
| **Preliminary Budget** | **$ 5.0** |

## Comparative Valuation

Galecto Biotech a Swedish private biotechnology company was founded in 2011.

They are developing a galectin-3 inhibitor, TD139, to treat idiopathic pulmonary fibrosis (IPF), which is a progressive, irreversible and ultimately fatal lung disease that has poor prognosis and no effective therapies.

In their C-round Galecto Biotech raised $95M with Ysios Capital and Orbimed in 2018, while in Phase II. They were offered a buy-out by Bristol Myers Squibb in 2019, the size of the deal was $444M.

# appendix



# Galectin Inhibitor Rx Drug Candidate

- Blocks virus entry to human cells by binding to coronavirus spike-protein.
- Expected to improve innate and adaptive immune system responses.
- May provide protection against SARS-CoV-2 exposure, as well as being an effective treatment.






Specific quantitative benefits to be established in trials.

# Antiviral - Block Cell or Virus?

## Mechanisms of Action

- Bind to the virus acting as an entry inhibitor.
- Binding to the virus soaks up the virion and the liver filters the galectin inhibitor with virion attached.
- Throttle the trafficking of macrophages to the site of infection.
- Remove plaque on T-cells results in improved response.



# Immunomodulatory




## Improved Immune Response

- High Galectin-3 forms plaque on the T-cell resulting in poor viral control.
- Removing Galectin-3 results in improved viral control.
- Eliminates T-cell anergy and Galectin effect which is also prevalent in cancer.